4CDA0A9D-18E2-4FDB-939E-4C4F29C063F9_edited.jpg
SPRYE_0266 full copy.jpg

Dr. Maysa Alavi, MD

Physician Specializing in Functional And Psychedelic Medicine

Phone:

929-DR-MAYSA

Email:

Address:

Spyre Center

1772 Prytania St.

Suite 205 & 206
New Orleans, LA 70130

A Bit About The Doctor

Dr. Maysa Alavi, MD is a board-certified physician and nationally recognized practitioner in psychedelic therapies and integrative medicine, uniting cutting-edge Western science with Eastern wellness philosophies to heal both mind and body. She humanizes health care by developing trusted personal relationships with her clients, empowering them to understand the root causes of their dis-ease and helping them connect with their own “inner healing intelligence” for long-term wellness. This goes above and beyond typical “symptom management medicine” by identifying and bringing awareness to the issue’s origin and its perpetuating and mediating factors. 

 

Dr. Maysa specializes in the groundbreaking field of psychedelic assisted therapies including Ketamine administration and infusions to treat depression, anxiety, PTSD, OCD, addictions, substance use disorders, migraines, pain and other conditions. She helps clients prepare for and integrate their psychedelic experiences for lasting benefits, while supporting them through whatever arises in their sessions. Dr. Maysa works with clients to develop balanced healing plans that combine psychedelic therapies and genomic analysis with wellness approaches that nurture mental, spiritual, and emotional health like breath work, meditation, yoga, stress reduction, nutrition, guided visualizations and sleep optimization. 

 

Dr. Maysa has studied at best-in-class institutions and organizations including The University of Southern California, University of Texas, UCLA, Institute for Functional Medicine, Dr. Andrew Weil Foundation, Multidisciplinary Association for Psychedelic Studies (MAPS), and COMPASS Pathways. She is currently serving as a study-site physician and therapist for the MAPS phase 3 clinical trial investigating the use of MDMA assisted therapy for the treatment of PTSD.